CLL Patients Faced Higher Atrial Fibrillation Risk

A 2026 study linked chronic lymphocytic leukemia and BTK inhibitor use to elevated cardiac risks.

Updated on Oct. 12, 2026 in Cancer

CLL Patients Faced Higher Atrial Fibrillation Risk

Live Poll

Do you trust findings that suggest certain cancer treatments carry higher cardiovascular risks for patients?

A study presented at the 2026 ASCO Annual Meeting found that 13.1% of 233,362 newly diagnosed CLL/SLL patients developed atrial fibrillation within one year. Patients diagnosed with this heart rhythm disorder faced significantly higher rates of stroke, bleeding, and heart failure.

Why it matters

Understanding the cardiac risks associated with leukemia treatments and diagnosis is essential for clinicians managing long-term patient health. The findings highlight the importance of cardiac monitoring for those undergoing specific therapies for chronic lymphocytic leukemia.

Researchers analyzed 233,362 newly diagnosed CLL/SLL patients, finding a 13.1% atrial fibrillation incidence rate within one year. Patients with the condition experienced a 54.5% heart failure rate, compared to 18.9% for those without it.

The players

ASCO

The American Society of Clinical Oncology is a professional organization representing physicians and other health care professionals who care for people with cancer.

The details

Using the Symphony Health database, researchers observed that 16.0% of patients treated with ibrutinib developed atrial fibrillation, compared to 13.0% for acalabrutinib and 11.0% for zanubrutinib. Among those treated with zanubrutinib, 4.8% experienced a stroke, while 12.2% of ibrutinib-treated patients with atrial fibrillation suffered a stroke.

The study was presented at the ASCO Annual Meeting in June 2026.

The Big Picture

This study follows the established pattern of clinical data dissemination at the ASCO Annual Meeting to update professional treatment guidelines. The findings underscore the evolving focus on secondary cardiac monitoring in oncology as patients live longer with managed leukemia.

Patients undergoing treatment for CLL should discuss the potential cardiac side effects of BTK inhibitors with their oncology care teams. Regular heart monitoring may be necessary for those with pre-existing risk factors to mitigate the risk of stroke or heart failure.

The takeaway

Patients diagnosed with CLL should prioritize cardiac screenings due to the statistically significant link between the disease, certain medications, and heart-related complications. Proactive communication with healthcare providers remains the most effective strategy for managing these systemic risks.